Apr 2 |
Genprex Collaborators Publish Positive Preclinical Data with NPRL2 Gene Therapy Utilizing Oncoprex® Delivery System
|
Mar 19 |
Genprex Announces $6.5 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
|
Mar 19 |
Genprex falls 10% after pricing its offering to raise $6.5M
|
Mar 12 |
Genprex Receives Notice of Patent Grant for Korean Patent Claiming Reqorsa® Immunogene Therapy with PD-1 and PD-L1 Antibodies to Treat Cancers
|
Mar 6 |
Genprex Collaborators to Present Positive Preclinical Data on the Use of Reqorsa® and on NPRL2 Gene Therapy Utilizing Non-Viral Oncoprex® Delivery System for the Treatment of Lung Cancers at the 2024 AACR Annual Meeting
|
Feb 7 |
Genprex Expands Nonclinical Programs into New Therapeutic Indications with Research Collaborators
|
Feb 6 |
Genprex to Present at Upcoming BIO CEO & Investor Conference
|
Feb 5 |
Genprex Announces First Patient Dosed in Phase 2a Expansion of Acclaim-1 Clinical Study of Reqorsa® Therapy in Combination with Tagrisso® to Treat Non-Small Cell Lung Cancer
|
Jan 31 |
Why AMD Shares Are Trading Lower? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
|
Jan 31 |
Crude Oil Down 2%; Alphabet Shares Fall After Q4 Results
|